OptumRx generic pipeline forecast
|
|
|
- Lee Peters
- 6 years ago
- Views:
Transcription
1 OptumRx generic pipeline forecast 2017 DAYTRANA Noven Therapeutics methylphenidate Transdermal patch All 2017 NORVIR AbbVie ritonavir Capsule; tablet All 2017 PROVENTIL HFA Merck albuterol sulfate Inhalation All 2017 TRAVATAN Z Alcon/Novartis travoprost Ophthalmic All 2017 ZAVESCA Actelion miglustat Capsule All 2017 SPRIX Egalet ketorolac Intranasal All 2017 TRACLEER Actelion bosentan Tablet All 2017 BETIMOL Oak/Akorn timolol Ophthalmic All H SYPRINE Valeant trientine Capsule All H BYETTA AstraZeneca exenatide Subcutaneous All H FENTORA Teva fentanyl Tablet, buccal All H ADCIRCA Eli Lilly/United Therapeutics tadalafil Tablet All INVANZ Merck ertapenem Intravenous All MENOSTAR Bayer estradiol Transdermal patch All GANIRELIX Organon/Merck ganirelix acetate Injection All KALETRA AbbVie lopinavir/ritonavir Tablet All REYATAZ Bristol-Myers Squibb atazanavir Capsule All SUSTIVA Bristol-Myers Squibb efavirenz Tablet 600 mg VIAGRA Pfizer sildenafil Tablet All VIREAD Gilead tenofovir disoproxil fumarate Tablet 300 mg ADVAIR DISKUS GlaxoSmithKline fluticasone/salmeterol xinafoate Inhalation All 2018 MINIVELLE Noven estradiol Transdermal patch All 2018 PROAIR HFA Teva albuterol sulfate Inhalation All 2018 SAMSCA Otsuka tolvaptan Tablet All 2018 TRISENOX Cephalon/Teva arsenic trioxide Intravenous All 2018 optum.com/optumrx 1
2 ZYTIGA Janssen abiraterone Tablet All 2018 THALOMID Celgene thalidomide Capsule All 2018 EPOGEN epoetin alfa Amgen PROCRIT epoetin alfa Janssen SUPRENZA Citius/Akrimax phentermine Subcutaneous; intravenous Subcutaneous; intravenous Tablet, orally disintegrating All All All H ISTALOL Valeant timolol Ophthalmic All H ZORTRESS Novartis everolimus Tablet All Q RITUXAN Genentech/Roche/Biogen Idec FORFIVO XL IntelGenX/Edgemont bupropion rituxumab Intravenous All Q All ISTODAX Celgene romidepsin Intravenous All MAKENA Lumara Health/Amag Pharmaceuticals hydroxyprogesterone caproate Intramuscular All TREXIMET Pernix naproxen/sumatriptan succinate Tablet All SENSIPAR Amgen cinacalcet Tablet All NUVARING Merck etonogestrel/ethinyl estradiol Vaginal ring All INVEGA TRINZA Janssen paliperidone palmitate Intramuscular, extended-release All ABSTRAL Sentynl fentanyl citrate Tablet, sublingual All EMSAM Somerset/Mylan selegiline Transdermal patch All REMODULIN United Therapeutics treprostinil Injection All LEVITRA GSK/Bayer vardenafil Tablet All Q LETAIRIS Gilead Sciences ambrisentan Tablet All Q ACANYA Valeant clindamycin/benzoyl peroxide Gel All AMPYRA Acorda dalfampridine All XENICAL Roche orlistat Capsule All MOVIPREP Salix/Valeant PEG-3350/sodium sulfate/sodium chloride/potassium chloride/sodium ascorbate/ascorbic acid Oral solution All TOLAK Hill Dermaceuticals fluorouracil Cream All CIALIS Eli Lilly tadalafil Tablet All ALOXI Helsinn/Eisai palonosetron Intravenous All PYLERA Allergan/Aptalis bismuth subcitrate potassium/metronidazole/tetracycline Capsule All Q optum.com/optumrx 2
3 RAPAFLO Allergan silodosin Capsule All Q ENBREL Amgen etanercept Subcutaneous All Q NEULASTA Amgen pegfilgrastim Subcutaneous All Q STAXYN Bayer vardenafil Tablet, orally disintegrating All FINACEA Bayer azelaic acid Gel All PULMICORT Flexhaler AstraZeneca budesonide Inhalation All ASTAGRAF XL Astellas tacrolimus BASAGLAR Eli Lilly/Boehringer Ingelheim Capsule, extendedrelease All insulin glargine recombinant Subcutaneous All CANASA Forest/Allergan mesalamine Rectal suppository All ELIDEL Valeant pimecrolimus Cream All XOLAIR Roche/Genentech omalizumab Intravenous All s CUVPOSA Merz glycopyrrolate Oral solution All 2019 ROZEREM Takeda ramelteon Tablet All 2019 TARCEVA OSI Pharma/Genentech/Pfizer erlotinib Tablet All 2019 OMNARIS Sunovion/Takeda ciclesonide Intranasal All H HERCEPTIN Genentech/Roche trastuzumab Intravenous All Q BEPREVE Bausch & Lomb/Valeant bepotastine Ophthalmic All LATUDA Sunovion lurasidone Tablet All TEKTURNA Novartis aliskiren Tablet All ZYCLARA Medicis imiquimod Cream All ADVATE Baxalta antihemophilic factor (recombinant), plasma/albumin-free method Intravenous All GILENYA Novartis fingolimod Capsule All KORLYM Corcept mifepristone Tablet All RANEXA Gilead ranolazine All AZASITE Akorn azithromycin Ophthalmic All EMEND Merck fosaprepitant dimeglumine Intravenous All FASLODEX AstraZeneca fulvestrant Intramuscular All ACTEMRA Roche/Chugai tocilizumab Intravenous; subcutaneous All BENEFIX Pfizer coagulation factor IX (recombinant) Intravenous All optum.com/optumrx 3
4 CETROTIDE EMD Serono cetrorelix Subcutaneous All EXJADE Novartis deferasirox Tablet All FLECTOR Pfizer diclofenac epolamine Transdermal patch All VESICARE Astellas solifenacin Tablet All EPANED KIT Silvergate enalapril Oral solution All DYLOJECT Hospira/Pfizer/ Javelin diclofenac Intravenous All LEVEMIR Novo Nordisk insulin detemir recombinant Subcutaneous All LYRICA Pfizer pregabalin Capsule; solution All RESCRIPTOR ViiV Healthcare delavirdine Tablet All FIRAZYR Shire icatibant acetate Subcutaneous All AVASTIN Genentech bevacizumab Intravenous All STRIANT Auxilium testosterone Tablet All TORISEL Pfizer temsirolimus Injection All FORTEO Eli Lilly teriparatide Injection All EDLUAR Meda/Orexo zolpidem Tablet, sublingual All YOSPRALA Aralez aspirin/omeprazole Tablet, delayedrelease All MYOBLOC US WorldMeds botulinum toxin type B Intramuscular All ORENCIA Bristol-Myers Squibb abatacept Intravenous; subcutaneous All CYSTARAN Sigma Tau cysteamine hydrochloride Ophthalmic All JADENU Novartis deferasirox Tablet All VERMOX Janssen mebendazole Tablet, chewable All OSMOPREP Salix sodium phosphate/sodium phosphate Tablet All TREANDA Cephalon; Teva bendamustine hydrochloride Intravenous All AMELUZ Biofrontera aminolevulinic acid Gel All DUREZOL Alcon/Novartis difluprednate Ophthalmic All APTENSIO XR Rhodes methylphenidate + = may launch during the stated date or later Capsule, extendedrelease All optum.com/optumrx 4
5 optum.com/optumrx The information contained herein is compiled from various sources and is provided for informational purposes only. Due to factors beyond the control of OptumRx, information related to prospective drug launches is subject to change without notice. This information should not be solely relied upon for formulary decision-making purposes. OptumRx specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum company a leading provider of integrated health services. Learn more at optum.com. All Optum trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx. RxOutlook is published by the OptumRx Clinical Services Department Optum, Inc. All rights reserved. ORX6204B_ optum.com/optumrx 5
OptumRx generic pipeline forecast
OptumRx generic pipeline forecast 2017 Daytrana methylphenidate Noven Therapeutics Transdermal patch All 2017+ Epiduo adapalene/benzoyl peroxide Endo Gel All 2017+ Norvir ritonavir AbbVie Capsule; tablet
OptumRx generic pipeline forecast
OptumRx generic pipeline forecast 2018 DAYTRANA methylphenidate Noven Therapeutics Transdermal patch All 2018 NORVIR ritonavir AbbVie Capsule; tablet All 2018 PROVENTIL HFA albuterol sulfate Merck Inhalation
ESTIMATED LAUNCH DATE* Sensipar cinacalcet Amgen Mar 2018 Endocrine Disorders High. Altoprev lovastatin ER Andrx Mar 2018 High Blood Cholesterol Low
Topicort 0.25% Topical Spray desoximetasone topical spray Taro Mar 2018 Skin Sensipar cinacalcet Amgen Mar 2018 Endocrine Disorders High Altoprev lovastatin ER Andrx Mar 2018 High Blood Cholesterol Ketek
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates July 2018 TRADE NAME (generic name) or generic name ADVAIR DISKUS (fluticasone-salmeterol aer powder ba 100-50 mcg/dose) Brand Addition ADVAIR
2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
Notice of Mid-Year Changes to 2019 Paramount Enhanced Formulary
Notice of Mid-Year s to 2019 Paramount Enhanced Formulary Paramount Elite (HMO) may immediately remove a brand name drug on our List if we are replacing it with a new generic drug that will appear on the
NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 (UPDATE AS OF NOVEMBER 30, HIGHLIGHTED)
HUMAN DRUGS NEW PATENTED MEDICINES REPORTED TO PMPRB 2011 COMPANY BRAND NAME CHEMICAL NAME DIN THERAPEUTIC USE DATE OF FIRST SALE Abbott Laboratories Limited Norvir 100 mg/tablet ritonavir 02357593 HIV
ANTIDEPRESSANTS. Details. Step Therapy 2017 Last Updated: 5/23/2017
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG FETZIMA CAPSULE
Memorial Hermann Advantage HMO February 2019 Formulary Addendum
Memorial Hermann Advantage HMO February 2019 Formulary Addendum Changes may have occurred since the printing of your current Memorial Hermann Advantage HMO Formulary. Medications that may have been added
ANTIDEPRESSANTS. Details. Step Therapy 2018 Last Updated: 8/21/2018
ANTIDEPRESSANTS EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL FETZIMA
3 Tier Formulary Additions
3 Tier Formulary Additions Drug Name Tier Category Management ACCU-CHECK GUIDE ME GLUCOSE METER 3 Diabetic Supplies Step Therapy applies pyridostigmine bromide 60mg/5ml syrup 1 Antimyasthenic Agents New
PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
Medication and Dose 10/04/ /05/2016 Total % Change Since 10/2012 ABILIFY 10 MG TABLET $18.76 $ %
Table Comparing NADAC prices for select brand name prescription medications on October 4, 2012 and October 5, 2016 to show how much prices have gone up for these medications. These medications increased
UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting
1. Call to order: The meeting was called to order at 7:10 a.m. UPMC for You Pharmacy and Therapeutics Committee Meeting July 27, 2010 meeting 2. Review of the minutes: The minutes of the April 6, 2010
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Health Partners Medicare Prime 2019 Formulary Changes
Health Partners Medicare Prime 2019 Formulary Changes Changes occur, for example, because new drugs come on the market, a drug is moved to a different cost-sharing level (tier), or a generic version becomes
CONTACT POLPHARMA GROUP POLPHARMA B2B
DOSSIER FDFLIST Product name Pharmaceutical form Strength Reference Therapeutic class ALIMENTARY TRACT & METABOLISM 1. Esomeprazole sodium or injection 40 mg Nexium / AstraZeneca Antiulcerant 2. Omeprazole
2019 Drug List Negative Changes
2019 Drug List Negative Changes Updated 03/26/2019 If you are taking a drug that is removed from the formulary (also known as the Drug List), we will tell you. We will also tell you if we add any restrictions
Step Therapy Criteria
ADCIRCA ADCIRCA Coverage will be provided if the member has filled a prescription for sildenafil (at least a 30 day supply within the past 365 ) ELIDEL 76-F ELIDEL Coverage will be provided if the member
PULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
TRICARE Uniform Formulary. Pre-Authorization Requirements
TRICARE Uniform Formulary Pre-Authorization Requirements The Department of Defense (DoD) requires pre-authorization on select medications. These medications are on the DoD s pre-authorization list because
JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.
ANTI DIABETICS BYDUREON 2 MG SUBCUTANEOUS JANUVIA 25 MG TABLET EXTENDED RELEASE SUSPENSION JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET
TECHNICAL APPENDIX: A PERSPECTIVE ON PRESCRIPTION DRUG COPAYMENT COUPONS
TECHNICAL APPENDIX: A PERSPECTIVE ON PRESCRIPTION DRUG COPAYMENT COUPONS METHODS FOR DETERMINING COPAY COUPON STATUS The copay coupon information comes from www.internetdrugcoupons.com (IDC). These data
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
List of Designated High-Cost Drugs
List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at
Step Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
Aetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
J Jubilant Pharma Group, catering to Dosage
DOSAGE FORMULATIONS Jubilant Generics, is one of the business arms of J Jubilant Pharma Group, catering to Dosage Formulations (DF) & Active Pharmaceutical Ingredients (API) business segment across developed
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
APREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE
APREPITANT Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil Oral Tablet 150, 200, 250, 50
MEDICAID QUANTITY LIMIT DRUG LIST
MEDICAID QUANTITY LIMIT DRUG LIST PH51-R-02162018 Brand Name Generic Name Dosage Form Tier Quantity Limit Details Cambia Diclofenac Potassium PACK Tier 2 QL: 9 per 30 days Fentanyl (12 Mcg/Hr, 25 Mcg/
Recommended comparator products: Medicines for HIV/AIDS and related diseases
Recommended comparator products: Medicines for HIV/AIDS and related diseases Comparator products should be purchased from a well regulated market with stringent regulatory authority 1. Invited medicinal
Health Net Health Plan of Oregon, Inc. Oregon Drugs with a quantity limit Effective January 1, 2015 (Published December 15, 2014)
Health Net Health Plan of Oregon, Inc. Oregon Drugs with a quantity limit Effective January 1, 2015 (Published December 15, 2014) Abstral SL Actonel 35mg Limited to 4 s per month. Actonel 5,30mg adapalene
Select Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18
Granite Alliance Insurance Company (PDP) 2018 Step Therapy Criteria Last Updated: 10/23/18 Granite Alliance requires step therapy for certain drugs. This means prior to receiving a drug with a step therapy
Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015
J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
MDwise Self-Administered Codes for Medical
The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively
PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION
Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate
2019 Drug List Negative Changes
2019 Drug List Negative Changes Updated 03/26/2019 If you are taking a drug that is removed from the formulary (also known as the Drug List), we will tell you. We will also tell you if we add any restrictions
2014 Quantity Limits (QL) Criteria
2014 Quantity Limits (QL) Criteria Certain drugs covered through your EmblemHealth Medicare HMO/PPO Medicare Plan are covered for only a limited quantity. We do this to ensure compliance with the US Food
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude
INSIGHT on the Issues
INSIGHT on the Issues AARP Public Policy Institute Rx Watchdog Report: Drug Prices Continue to Climb Despite Lack of Growth in General Inflation Rate AARP s Public Policy Institute finds that average manufacturer
5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release
5-ASA Dipentum 250 mg capsule Lialda 1.2 gram tablet,delayed release You are required to have previous therapy with balsalazide, Delzicol, Apriso, or Asacol HD before we will cover Lialda or Dipentum.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
2016 Drug Blockbusters and Patent Expiration Review
February 23, 2016 2016 Drug Blockbusters and Patent Expiration Review Nicolle Rychlick, PharmD Director, Clinical Integration and Implementation 1 Disclosure Nicolle Rychlick, Pharm.D., has nothing to
Therapeutic Class Indications Effective
Mortar & Pestle A Publication of Walgreens Health Initiatives July 30, 2009 A publication created especially for our clients and associates, delivering up-to-date information about brand-name and generic,
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNCA.01 Effective Date: 11.16.16 Last Review Date: 04.18 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important
Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum
Superior Select Health Plans: Tribute-1 Tier May 2018 Formulary Addendum Below is a list formulary changes for the benefit year 2018. This is not a complete list of drugs covered by the Part D plan. The
Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol
Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
ANTICONVULSANTS. Details. Step Therapy Criteria Date Effective: April 1, 2019
Step Therapy Date Effective: April 1, 2019 ANTICONVULSANTS APTIOM TABLET 200 MG ORAL APTIOM TABLET 400 MG ORAL APTIOM TABLET 600 MG ORAL APTIOM TABLET 800 MG ORAL BANZEL SUSPENSION 40 MG/ML ORAL BANZEL
2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
Michigan Pharmacy and Therapeutics Committee September 11, Minutes
Michigan Pharmacy and Therapeutics Committee September 11, 2018 Minutes Attendees: Vickie Tutag Lehr, Brian Peltz, Jayne Courts, Rony Foumia, Andrew Mac, Andrew Adair, Margo Farber, David Neff, Brad Uren
2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
Quantity Limits 2016 Paramount Medicare Formulary Formulary ID: Version 26 Updated: 11/1/2016
Quantity Limits 2016 Paramount Medicare Formulary Formulary ID: 16162 Version 26 Updated: 11/1/2016 ANALGESICS acetaminophen w/ codeine (300-15 mg, 300-30 mg, 300-60 mg) acetaminophen w/ codeine soln 120-12
Quarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice The formulary changes listed in the table below were reviewed and approved at our second quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina
South Carolina Department of Health and Human Services Post Office Box 8206 Columbia, South Carolina 29202-8206 Pharmacy and Therapeutics (P&T) Committee Meeting MINUTES 1. Call to Order A meeting of the
Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir
Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires
Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.92 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
Pharmacy and Therapeutics (P&T) Committee Provider Update
Pharmacy and Therapeutics (P&T) Committee Provider Update THIRD QUARTER 2017 Presbyterian Health Plan, Inc. Presbyterian Insurance Company, Inc. P&T Committee Decisions Effective August 15, 2017 Dear Healthcare
University System of Georgia Prior Authorization, Step Therapy and Quantity Limit List (Updated 1/1/2016)
University System of Georgia, Step Therapy and Quantity Limit List (Updated 1/1/2016) (PA) Your doctor will need to obtain a prior authorization for the drugs listed below, before your prescription drug
Step Therapy Approval Criteria
Effective Date: 01/01/2019 This document contains for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab) 5. Imitrex Injection vial
Pharmacy Clinical Prior Authorization Assistance Chart Effective February 2018
About Pharmacy Clinical Prior Authorizations Clinical prior authorizations (PA) are based on evidence-based clinical criteria and nationally recognized peer-reviewed information. The PA may apply to an
Drug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
Your prescription benefit updates Formulary Updates - Effective January 1, 2019
Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will
ABILIFY INJ. Products Affected Step 2: ABILIFY MAINTENA PREFILLED SYRINGE 300 MG INTRAMUSCULAR ABILIFY MAINTENA PREFILLED SYRINGE 400 MG INTRAMUSCULAR
ABILIFY INJ ABILIFY MAINTENA PREFILLED SYRINGE 300 MG ABILIFY MAINTENA PREFILLED SYRINGE 400 MG ABILIFY MAINTENA SUSPENSION RECONSTITUTED ER 300 MG Claim will pay automatically for ABILIFY MAINTENA if
Quarterly pharmacy formulary change notice
Provider Bulletin October 2018 Quarterly pharmacy formulary change notice The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. The changes listed in the table
Pain Oral-Intranasal Fentanyl (Abstral, Actiq, Fentora, Lazanda, Onsolis, Subsys)
Pennsylvania Employees Benefit Trust Fund (PEBTF) and n- Medicare Eligible Retired Employees Health Program (REHP), Step Therapy and Quantity Limit List Your doctor needs to get prior authorization for
Recommended Comparator Products: Medicines for HIV/AIDS and Related Diseases
Medicines for HIV/AIDS and Related Diseases Comparator products should be purchased from a well-regulated market with a stringent regulatory authority. 1 Invited medicinal products Abacavir, 60 mg, 300
Quarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Summary of change: The Pharmacy and Therapeutics Committee (P&T) reviewed and approved the formulary changes listed in the table below on March 29, 2016. What
formulations Product List- row
Solid Dosage formulations Product List- row Therapy Products Strengths Innovator Brand Benazepril + HCTZ 5+ 6.25mg, 10+12.5mg, 20+12.5mg, 20+25mg Brand Name Lotensin HCT Company Validus Pharma Candesartan
Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria
ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least
September 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to UCare (approved drug list). These changes are reviewed based
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List
Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea
METABOLIC, IMMUNE DISORDERS OR INHERITED RARE DISEASE ALPHA-1 PROTEINASE INHIBITORS ARANESP BLOOD CELL DEFICIENCY ARANESP ARCALYST
PRIOR AUTHORIZATION LIST (SUBJECT TO CHANGE) MEDICATION THERAPEUTIC CATEGORY MODULE ACTEMRA INFLAMMATORY CONDITIONS ACTEMRA ADCIRCA PULMONARY HYPERTENSION PDE-5 INHIBITORS FOR PAH ADDYI SEXUAL DISORDERS
The following are J Code requirements
The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based
Drug Pipeline Monthly Update
Drug Pipeline Monthly Update Critical updates in an ever changing environment December 2017 New drug information Juluca (dolutegravir/rilpivirine): Viiv Healthcare received U.S. Food and Drug Administration
Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
Prescription benefit updates Individual/small group
Prescription benefit updates Individual/small group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps
SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION
Saskatchewan Health Drug Plan and Extended Benefits Branch January 2005 Bulletin #101 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN UPDATE TO THE 54th EDITION NEW FULL FORMULARY LISTING: The
RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)
INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193
Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria
Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS. HLC174A October Usha Nagavarapu Project Analyst
GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley,
Quarterly pharmacy formulary change notice
MEDICAID PROVIDER BULLETIN October 2018 The formulary changes listed in the table below were reviewed and approved at the second-quarter 2018 Pharmacy and Therapeutics Committee meeting. Effective October
Drug Pipeline Monthly Update
Drug Pipeline Monthly Update Critical updates in an ever changing environment September 2018 New drug information Altreno (tretinoin): Ortho Dermatologic received Food and Drug Administration (FDA) approval
ANTICONVULSANT THERAPY
Network Health Insurance Corporation NetworkCares Step Therapy Last Updated: 7/2017 ANTICONVULSANT THERAPY Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200
3 RD QUARTER 2015 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES
September 2015 3 RD QUARTER 2015 UPDATE CHANGES TO THE HIGHMARK DRUG FORMULARIES Following is the 3 rd Quarter 2015 update to the Highmark Drug Formularies and pharmaceutical management procedures. The
Russian pharmaceutical market: 2016 vs Anna Ermolaeva AlphaRM General Manager
Russian pharmaceutical market: 2016 vs 2017 Anna Ermolaeva AlphaRM General Manager Russian pharmaceutical market volume 16 ~1,13 (trln, RUB)* & ~5,3 (bln, units) Including Food Supplements (FS), Medical
Oregon Health Plan prescription benefit updates
Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save
DOSSIER LIST. tlo_seledyn.pdf :38:01 CMY K CM MY CY
tlo_seledyn.pdf 1 22.08.2017 14:38:01 C M Y CM MY CY CMY K DOSSIER LIST AVAILABLE DOSSIERS THERAPEUTIC CLASS / MAIN INDICATION LACTOSE FREE ZONE IV CPP FEASIBILITY ALIMENTARY TRACT & METABOLISM 1. Esomeprazole
Volume 10; Number 4 February 2016
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
Quarterly pharmacy formulary change notice
Provider Bulletin June 24, 2016 Summary of change The Pharmacy and Therapeutics Committee reviewed and approved the formulary changes listed in the table below on March 29, 2016. What this means to you
March 2018 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
Drug Pipeline Monthly Update
Drug Pipeline Monthly Update Critical updates in an ever changing environment December 2018 New drug information Temixys (lamivudine/tenofovir disoproxil fumarate): The Food and Drug Administration (FDA)